Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1984 1
1985 1
1986 2
1987 2
1989 1
1991 2
1992 2
1995 3
1996 1
1997 3
1998 3
1999 2
2000 4
2002 2
2003 4
2004 2
2005 4
2006 1
2007 7
2008 4
2009 1
2010 3
2011 5
2012 5
2013 2
2014 2
2015 3
2016 3
2017 10
2018 6
2019 4
2020 5
2021 8
2022 5
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Extensive Stage Lung Small Cell Carcinoma"
Page 1
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Antonia SJ, et al. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269741 Free article. Clinical Trial.
BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. ...Eligible patients were 18 years of age or older, had limited-stage or extensive-stage SCLC, and had disease progression …
BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. ...E …
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP. Morgensztern D, et al. Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10. Clin Cancer Res. 2019. PMID: 31506387 Free PMC article. Clinical Trial.
PURPOSE: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. ...
PURPOSE: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therap …
Lung cancer.
Frödin JE. Frödin JE. Acta Oncol. 1996;35 Suppl 7:46-53. doi: 10.3109/02841869609101662. Acta Oncol. 1996. PMID: 9154094
These studies involve 28172 patients. Basic treatment for limited-stage small cell lung cancer (SCLC), is chemotherapy. Addition of radiotherapy to the primary tumor and mediastinum reduces local recurrence, prolongs long-term survival, and is o …
These studies involve 28172 patients. Basic treatment for limited-stage small cell lung cancer (SCLC), is chemot …
Consolidative thoracic radiotherapy for extensive stage small cell lung cancer.
Zhang X, Yu J, Zhu H, Meng X, Li M, Jiang L, Ding X, Sun X. Zhang X, et al. Oncotarget. 2017 Mar 28;8(13):22251-22261. doi: 10.18632/oncotarget.14759. Oncotarget. 2017. PMID: 28118612 Free PMC article. Review.
Extensive stage small cell lung cancer (ES-SCLC) represents approximately half of all diagnosed small cell lung cancer worldwide. It is notorious for a high risk of local recurrence although it's sensitive to chemothe …
Extensive stage small cell lung cancer (ES-SCLC) represents approximately half of all diagnosed small …
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.
Valette CA, Filleron T, Debieuvre D, Lena H, Pérol M, Chouaid C, Simon G, Quantin X, Girard N. Valette CA, et al. Respir Med Res. 2023 Nov;84:101012. doi: 10.1016/j.resmer.2023.101012. Epub 2023 Mar 27. Respir Med Res. 2023. PMID: 37307617
BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive entity of lung cancer with tendency toward early recurrence after first-line treatment. ...The purpose of the current analysis is to identify current patient profiles and treatment …
BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive entity of lung cancer with tendency toward earl …
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR, Alrajhi AM, Durand CR. Cooper MR, et al. Am J Ther. 2018 May/Jun;25(3):e349-e356. doi: 10.1097/MJT.0000000000000686. Am J Ther. 2018. PMID: 29722737 Review.
BACKGROUND: Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer diagnoses each year. ...DATA SOURCES: A literature search was conducted using Medline (1946-July week 1, 2017) and Embase (1996-2017 week 28) with the search te …
BACKGROUND: Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer diagnoses each year. …
Lung cancer: a review.
Cersosimo RJ. Cersosimo RJ. Am J Health Syst Pharm. 2002 Apr 1;59(7):611-42. doi: 10.1093/ajhp/59.7.611. Am J Health Syst Pharm. 2002. PMID: 11944603 Review.
Lung cancers can be broadly classified into two forms, small-cell carcinomas and non-small-cell carcinomas. ...Surgery plays a major role in managing stage I and stage II non-small-cell lung cancer and may be u …
Lung cancers can be broadly classified into two forms, small-cell carcinomas and non-small-cell carcinoma …
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Desai A, et al. Clin Lung Cancer. 2023 Dec;24(8):689-695.e1. doi: 10.1016/j.cllc.2023.09.001. Epub 2023 Sep 17. Clin Lung Cancer. 2023. PMID: 37880074 Free article.
BACKGROUND: Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While clinical trials have demonstrated its efficacy and safety, real-world data are limited. ...
BACKGROUND: Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While …
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Li D, Huang Z, Zhong J, Lin L, Zhang G, Zhuang W, Liu Z. Li D, et al. BMC Cancer. 2023 Aug 14;23(1):753. doi: 10.1186/s12885-023-11230-5. BMC Cancer. 2023. PMID: 37580661 Free PMC article. Clinical Trial.
BACKGROUND: Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10-15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly di …
BACKGROUND: Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10-15% of l …
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Gupta AR, et al. Future Oncol. 2021 Dec;17(34):4785-4795. doi: 10.2217/fon-2021-0517. Epub 2021 Aug 26. Future Oncol. 2021. PMID: 34435876 Free PMC article.
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as 'ear …
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and morta …
110 results